Identification

Name
Trandolapril
Accession Number
DB00519  (APRD01269)
Type
Small Molecule
Groups
Approved
Description

Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Trandolapril may be used to treat mild to moderate hypertension, to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, as an adjunct treatment for congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.

Structure
Thumb
Synonyms
  • Trandolaprilum
External IDs
RU 44570 / RU-44570
Product Ingredients
IngredientUNIICASInChI Key
Trandolapril hydrochloride3EY8XK2J4T87725-72-2QNSWMJYOGMUVGO-REWXTUPXSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MavikTablet4 mg/1OralAbbvie1996-04-262016-12-15Us
MavikCapsule2 mgOralBgp Pharma Ulc1998-01-14Not applicableCanada
MavikCapsule4 mgOralBgp Pharma Ulc2003-11-01Not applicableCanada
MavikTablet2 mg/1OralAbbvie1996-04-262017-07-31Us
MavikCapsule1 mgOralBgp Pharma Ulc1998-01-07Not applicableCanada
MavikTablet4 mg/1OralPhysicians Total Care, Inc.2004-06-25Not applicableUs
MavikTablet1 mg/1OralAbbvie1996-04-262017-06-30Us
MavikCapsule0.5 mgOralBgp Pharma Ulc1998-01-28Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Mylan-trandolaprilCapsule1 mgOralMylan PharmaceuticalsNot applicableNot applicableCanada
Mylan-trandolaprilCapsule4 mgOralMylan PharmaceuticalsNot applicableNot applicableCanada
Mylan-trandolaprilCapsule0.5 mgOralMylan PharmaceuticalsNot applicableNot applicableCanada
Mylan-trandolaprilCapsule2 mgOralMylan PharmaceuticalsNot applicableNot applicableCanada
TrandolaprilTablet1 mg/1OralTeva2007-02-072016-02-29Us00093 7325 01 nlmimage10 852d42da
TrandolaprilTablet2 mg/1OralCitron Pharma LLC2007-06-12Not applicableUs
TrandolaprilTablet4 mg/1OralDispensing Solutions, Inc.2007-02-07Not applicableUs00093 7327 01 nlmimage10 b02d580a
TrandolaprilTablet4 mg/1OralAurobindo Pharma2007-06-12Not applicableUs
TrandolaprilTablet4 mg/1OralAv Kare, Inc.2013-07-302016-10-13Us
TrandolaprilTablet4 mg/1OralEpic Pharma, LLC2015-03-31Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
TarkaTrandolapril (2 mg/1) + Verapamil hydrochloride (240 mg/1)Tablet, film coated, extended releaseOralPhysicians Total Care, Inc.2005-05-27Not applicableUs
TarkaTrandolapril (2 mg) + Verapamil hydrochloride (180 mg)Tablet, extended releaseOralAbbott2002-07-152010-11-12Canada
TarkaTrandolapril (4 mg/1) + Verapamil hydrochloride (240 mg/1)Tablet, film coated, extended releaseOralAbbvie1996-10-22Not applicableUs
TarkaTrandolapril (2 mg/1) + Verapamil hydrochloride (180 mg/1)Tablet, film coated, extended releaseOralAbbvie1996-10-22Not applicableUs
TarkaTrandolapril (2 mg/1) + Verapamil hydrochloride (180 mg/1)Tablet, film coated, extended releaseOralPhysicians Total Care, Inc.2009-01-01Not applicableUs
TarkaTrandolapril (2 mg) + Verapamil hydrochloride (240 mg)Tablet, extended releaseOralBgp Pharma Ulc2002-07-15Not applicableCanada
TarkaTrandolapril (4 mg) + Verapamil hydrochloride (240 mg)Tablet, extended releaseOralBgp Pharma Ulc2002-07-15Not applicableCanada
TarkaTrandolapril (2 mg/1) + Verapamil hydrochloride (240 mg/1)Tablet, film coated, extended releaseOralAbbvie1996-10-22Not applicableUs
TarkaTrandolapril (4 mg/1) + Verapamil hydrochloride (240 mg/1)Tablet, film coated, extended releaseOralPhysicians Total Care, Inc.2009-06-25Not applicableUs00074 3290 13 nlmimage10 ec1d766b
TarkaTrandolapril (1 mg) + Verapamil hydrochloride (240 mg)Tablet, extended releaseOralAbbott2002-07-152010-11-12Canada
International/Other Brands
Mavik
Categories
UNII
1T0N3G9CRC
CAS number
87679-37-6
Weight
Average: 430.5372
Monoisotopic: 430.246772208
Chemical Formula
C24H34N2O5
InChI Key
VXFJYXUZANRPDJ-WTNASJBWSA-N
InChI
InChI=1S/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)/t16-,18+,19-,20-,21-/m0/s1
IUPAC Name
(2S,3aR,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-octahydro-1H-indole-2-carboxylic acid
SMILES
[H][[email protected]@]12C[[email protected]](N(C(=O)[[email protected]](C)N[[email protected]@H](CCC3=CC=CC=C3)C(=O)OCC)[[email protected]@]1([H])CCCC2)C(O)=O

Pharmacology

Indication

For the treatment of mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure (CHF), to improve survival following myocardial infarction (MI) in individuals who are hemodynamically stable and demonstrate symptoms of left ventricular systolic dysfunction or signs of CHF within a few days following acute MI, and to slow progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy.

Structured Indications
Pharmacodynamics

Trandolapril is the ethyl ester prodrug of a nonsulfhydryl ACE inhibitor, trandolaprilat. Trandolapril is deesterified in the liver to the diacid metabolite, trandolaprilat, which is approximately eight times more active as an inhibitor of ACE than its parent compound. ACE is a peptidyl dipeptidase that is part of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure via a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may further sustain the effects of trandolaprilat by causing increased vasodilation and decreased blood pressure. The blood pressure lowering effect of trandolaprilat is due to a decrease in peripheral vascular resistance, which is not accompanied by significant changes in urinary excretion of chloride or potassium or water or sodium retention.

Mechanism of action

There are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Trandolaprilat, the active metabolite of trandolapril, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Trandolaprilat also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors.

TargetActionsOrganism
AAngiotensin-converting enzyme
inhibitor
Human
Absorption

~ 40-60% absorbed; extensive first pass metabolism results in a low bioavailability of 4-14%

Volume of distribution
  • 18 L
Protein binding

Serum protein binding of trandolapril is ~ 80% (independent of concentration and not saturable) while that of trandolaprilat is 65 to 94% (concentration-dependent and saturable).

Metabolism

Cleavage of the ester group of trandolapril, primarily in the liver, is responsible for conversion to trandolaprilat, the active metabolite. Seven other metabolites, including diketopiperazine and glucuronide conjugated derivatives of trandolapril and trandolaprilat, have been identified.

Route of elimination

After oral administration of trandolapril, about 33% of parent drug and metabolites are recovered in urine, mostly as trandolaprilat, with about 66% in feces.

Half life

The elimination half lives of trandolapril and trandolaprilat are about 6 and 10 hours, respectively, but, similar to all ACE inhibitors, trandolaprilat also has a prolonged terminal elimination phase that involves a small fraction of administered drug. This likely represents drug binding to plasma and tissue ACE. The effective half life of elimination for trandolaprilat is 16-24 hours.

Clearance
  • 52 L/h [After approximately 2 mg IV doses]
Toxicity

Most likely clinical manifestations of overdose are symptoms of severe hypotension. Most common adverse effects include cough, headache and dizziness. The oral LD50 of trandolapril in mice was 4875 mg/kg in males and 3990 mg/kg in females. In rats, an oral dose of 5000 mg/kg caused low mortality (1 male out of 5; 0 females). In dogs, an oral dose of 1000 mg/kg did not cause mortality and abnormal clinical signs were not observed.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Trandolapril Metabolism PathwayDrug metabolism
Trandolapril Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Trandolapril.Investigational
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Trandolapril.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Trandolapril.Approved, Investigational
AcebutololTrandolapril may increase the hypotensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Trandolapril.Approved, Investigational
AcemetacinThe therapeutic efficacy of Trandolapril can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
Acetylsalicylic acidThe therapeutic efficacy of Trandolapril can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Trandolapril.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Trandolapril.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Trandolapril.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Trandolapril.Approved, Investigational
AliskirenAliskiren may increase the hypotensive, nephrotoxic, and hyperkalemic activities of Trandolapril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Trandolapril.Approved
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Trandolapril.Experimental
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Trandolapril.Approved
AloxiprinThe therapeutic efficacy of Trandolapril can be decreased when used in combination with Aloxiprin.Experimental
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Trandolapril.Approved, Illicit, Investigational
AlprenololTrandolapril may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanTrandolapril may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Trandolapril.Experimental, Investigational
AmifostineTrandolapril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideAmiloride may increase the hyperkalemic activities of Trandolapril.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Trandolapril.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Trandolapril.Approved
Aminosalicylic AcidThe therapeutic efficacy of Trandolapril can be decreased when used in combination with Aminosalicylic Acid.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Trandolapril.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Trandolapril.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Trandolapril.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Trandolapril.Approved, Illicit
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Trandolapril.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Trandolapril.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Trandolapril.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Trandolapril is combined with Amyl Nitrite.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Trandolapril.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Trandolapril.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Trandolapril.Approved, Investigational
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Trandolapril.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Trandolapril.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Trandolapril.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Trandolapril.Approved, Investigational, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Trandolapril.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Trandolapril.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Trandolapril.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Trandolapril.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Trandolapril.Approved
AvanafilAvanafil may increase the antihypertensive activities of Trandolapril.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Trandolapril.Withdrawn
AzathioprineThe risk or severity of anemia and severe leukopenia can be increased when Trandolapril is combined with Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Trandolapril.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Trandolapril.Approved, Investigational
AzosemideAzosemide may increase the hypotensive activities of Trandolapril.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Trandolapril.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Trandolapril.Experimental
BarbitalBarbital may increase the hypotensive activities of Trandolapril.Illicit
BarnidipineTrandolapril may increase the antihypertensive activities of Barnidipine.Approved
BenazeprilTrandolapril may increase the hypotensive activities of Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Trandolapril.Experimental
BendroflumethiazideThe risk or severity of hypotension can be increased when Bendroflumethiazide is combined with Trandolapril.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Trandolapril.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Trandolapril.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Trandolapril.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Trandolapril.Approved
BepridilTrandolapril may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Trandolapril.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Trandolapril.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Trandolapril.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Trandolapril.Experimental
BimatoprostTrandolapril may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololTrandolapril may increase the hypotensive activities of Bisoprolol.Approved
BoceprevirThe serum concentration of Trandolapril can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Trandolapril.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Trandolapril.Approved, Investigational
BQ-123Trandolapril may increase the hypotensive activities of BQ-123.Investigational
BretyliumTrandolapril may increase the hypotensive activities of Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Trandolapril.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Trandolapril.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Trandolapril.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Trandolapril.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Trandolapril.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Trandolapril.Approved, Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Trandolapril.Experimental
BumetanideBumetanide may increase the hypotensive activities of Trandolapril.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Trandolapril.Approved, Investigational
BupranololTrandolapril may increase the hypotensive activities of Bupranolol.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Trandolapril.Approved
CadralazineCadralazine may increase the hypotensive activities of Trandolapril.Experimental
CafedrineTrandolapril may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Trandolapril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Trandolapril.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Trandolapril.Approved
CandoxatrilTrandolapril may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilTrandolapril may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe metabolism of Trandolapril can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe therapeutic efficacy of Trandolapril can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Trandolapril.Approved, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Trandolapril.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Trandolapril.Approved, Vet Approved, Withdrawn
CarteololTrandolapril may increase the hypotensive activities of Carteolol.Approved
CarvedilolTrandolapril may increase the hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Trandolapril.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Trandolapril.Approved, Investigational
CeliprololTrandolapril may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Trandolapril.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of hypotension can be increased when Chlorothiazide is combined with Trandolapril.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Trandolapril.Investigational, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Trandolapril.Approved, Investigational, Vet Approved
ChlorthalidoneThe risk or severity of hypotension can be increased when Chlorthalidone is combined with Trandolapril.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Trandolapril.Approved
CicletanineTrandolapril may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilTrandolapril may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Trandolapril.Approved, Investigational
CiprofloxacinThe risk or severity of ventricular arrhythmias can be increased when Trandolapril is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Trandolapril.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Clevidipine.Approved, Investigational
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Trandolapril.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Trandolapril.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Trandolapril.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Trandolapril.Approved
CloranololTrandolapril may increase the hypotensive activities of Cloranolol.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Trandolapril.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Trandolapril.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Trandolapril.Approved
CryptenamineTrandolapril may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Trandolapril.Approved, Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Trandolapril.Approved
CyclopenthiazideThe risk or severity of hypotension can be increased when Cyclopenthiazide is combined with Trandolapril.Experimental
CyclophosphamideThe risk or severity of adverse effects can be increased when Trandolapril is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Trandolapril.Approved, Investigational, Vet Approved
CyclothiazideTrandolapril may increase the hypotensive activities of Cyclothiazide.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Trandolapril is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Trandolapril.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Trandolapril.Approved, Investigational
DelaprilTrandolapril may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Trandolapril.Approved
DersalazineThe therapeutic efficacy of Trandolapril can be decreased when used in combination with Dersalazine.Investigational
DeserpidineTrandolapril may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Trandolapril.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Trandolapril.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Dexmedetomidine.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Trandolapril.Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Trandolapril.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Trandolapril.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Trandolapril is combined with Diclofenamide.Approved, Investigational
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Trandolapril.Approved, Investigational
DiethylnorspermineTrandolapril may increase the hypotensive activities of Diethylnorspermine.Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Trandolapril.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Trandolapril.Experimental
DiflunisalThe therapeutic efficacy of Trandolapril can be decreased when used in combination with Diflunisal.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Trandolapril.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Trandolapril.Approved, Investigational
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Trandolapril.Approved, Investigational
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Trandolapril.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Trandolapril is combined with Dinutuximab.Approved, Investigational
DipyridamoleThe risk or severity of adverse effects can be increased when Trandolapril is combined with Dipyridamole.Approved
DorzolamideTrandolapril may increase the hypotensive activities of Dorzolamide.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Trandolapril.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Trandolapril.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Trandolapril.Approved, Investigational
DrospirenoneTrandolapril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Trandolapril.Withdrawn
DuloxetineTrandolapril may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Trandolapril.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Trandolapril.Approved
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Trandolapril.Investigational
EfonidipineTrandolapril may increase the hypotensive activities of Efonidipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Trandolapril is combined with Empagliflozin.Approved
EnalaprilTrandolapril may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatTrandolapril may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Trandolapril.Experimental
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Trandolapril.Approved, Investigational
EpanololTrandolapril may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Trandolapril.Approved
EpitizideThe risk or severity of hypotension can be increased when Epitizide is combined with Trandolapril.Experimental
EplerenoneEplerenone may increase the hyperkalemic activities of Trandolapril.Approved
EpoprostenolTrandolapril may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Trandolapril.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Trandolapril.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Trandolapril.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Trandolapril.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Trandolapril.Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Trandolapril.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Trandolapril.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Trandolapril.Approved, Investigational
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Trandolapril.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Trandolapril.Approved
Etacrynic acidEtacrynic acid may increase the hypotensive activities of Trandolapril.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Trandolapril.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Trandolapril.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Trandolapril.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Trandolapril.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Trandolapril.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Trandolapril.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Trandolapril.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Trandolapril.Approved, Investigational
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Trandolapril.Approved
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Trandolapril.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Trandolapril.Experimental
FelodipineTrandolapril may increase the hypotensive activities of Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Trandolapril.Approved
FenoldopamTrandolapril may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Trandolapril.Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Trandolapril.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Trandolapril.Experimental
Ferulic acidTrandolapril may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Trandolapril.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Trandolapril.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Trandolapril.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Trandolapril.Experimental
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Trandolapril.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Trandolapril.Experimental
FosinoprilFosinopril may increase the hypotensive activities of Trandolapril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Trandolapril.Approved, Investigational, Vet Approved
FurosemideFurosemide may increase the hypotensive activities of Trandolapril.Approved, Vet Approved
GarlicThe serum concentration of Trandolapril can be decreased when it is combined with Garlic.Approved
GuacetisalThe therapeutic efficacy of Trandolapril can be decreased when used in combination with Guacetisal.Experimental
GuanabenzTrandolapril may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Trandolapril.Approved
GuanazodineTrandolapril may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineTrandolapril may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Trandolapril.Approved, Investigational
GuanoclorTrandolapril may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzTrandolapril may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanTrandolapril may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Trandolapril.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Trandolapril.Experimental
Hemoglobin crosfumarilThe therapeutic efficacy of Trandolapril can be decreased when used in combination with Hemoglobin crosfumaril.Experimental
HeparinThe risk or severity of hyperkalemia can be increased when Trandolapril is combined with Heparin.Approved, Investigational
HexamethoniumTrandolapril may increase the hypotensive activities of Hexamethonium.Experimental
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Trandolapril.Withdrawn
HexobarbitalHexobarbital may increase the hypotensive activities of Trandolapril.Approved
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Trandolapril.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Trandolapril.Experimental
HydralazineHydralazine may increase the hypotensive activities of Trandolapril.Approved
HydrochlorothiazideThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Trandolapril.Approved, Vet Approved
HydroflumethiazideThe risk or severity of hypotension can be increased when Hydroflumethiazide is combined with Trandolapril.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Trandolapril.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Trandolapril.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Trandolapril.Approved, Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Trandolapril.Approved, Investigational
ImidaprilTrandolapril may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Trandolapril.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Trandolapril.Approved
IndapamideThe risk or severity of hypotension can be increased when Indapamide is combined with Trandolapril.Approved
IndenololTrandolapril may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Trandolapril.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Trandolapril.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Trandolapril.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Trandolapril.Withdrawn
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Trandolapril.Experimental
IproclozideIproclozide may increase the hypotensive activities of Trandolapril.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Trandolapril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Trandolapril.Approved, Investigational
IronIron can cause a decrease in the absorption of Trandolapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Trandolapril is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Trandolapril.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Trandolapril.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Trandolapril is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Trandolapril is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Trandolapril.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Trandolapril.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Trandolapril.Experimental
KetanserinKetanserin may increase the hypotensive activities of Trandolapril.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Trandolapril.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Trandolapril.Approved
LabetalolTrandolapril may increase the hypotensive activities of Labetalol.Approved
LacidipineTrandolapril may increase the hypotensive activities of Lacidipine.Approved, Investigational
Lanthanum carbonateThe serum concentration of Trandolapril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostTrandolapril may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Trandolapril.Approved, Investigational
LercanidipineTrandolapril may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Trandolapril is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Trandolapril.Approved, Investigational
LevodopaTrandolapril may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Trandolapril.Approved, Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Trandolapril.Approved
LinsidomineTrandolapril may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilTrandolapril may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Trandolapril.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Trandolapril.Approved
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Trandolapril.Experimental
LofexidineTrandolapril may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Trandolapril.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Trandolapril.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Trandolapril.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Trandolapril.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Trandolapril.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Trandolapril.Approved, Investigational
MacitentanTrandolapril may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Trandolapril.Approved
ManidipineTrandolapril may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Trandolapril is combined with Mannitol.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Trandolapril.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Trandolapril.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Trandolapril.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Trandolapril.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Trandolapril.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Trandolapril.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Trandolapril can be decreased when used in combination with Mesalazine.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Trandolapril.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Trandolapril.Approved, Investigational, Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Trandolapril.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Trandolapril is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Trandolapril.Approved
MethoserpidineTrandolapril may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of hypotension can be increased when Methyclothiazide is combined with Trandolapril.Approved
Methyl salicylateThe therapeutic efficacy of Trandolapril can be decreased when used in combination with Methyl salicylate.Approved, Vet Approved
MethyldopaTrandolapril may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Trandolapril.Approved, Investigational
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Trandolapril.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Trandolapril.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Trandolapril.Approved
MetipranololTrandolapril may increase the hypotensive activities of Metipranolol.Approved
MetolazoneThe risk or severity of hypotension can be increased when Metolazone is combined with Trandolapril.Approved
MetoprololMetoprolol may increase the hypotensive activities of Trandolapril.Approved, Investigational
MetyrosineTrandolapril may increase the hypotensive activities of Metyrosine.Approved
MibefradilTrandolapril may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Trandolapril.Approved, Illicit
MinaprineMinaprine may increase the hypotensive activities of Trandolapril.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Trandolapril.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Trandolapril.Investigational
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Trandolapril.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Trandolapril.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Trandolapril.Approved, Investigational
MoexiprilTrandolapril may increase the hypotensive activities of Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Trandolapril.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Trandolapril.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Trandolapril.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Trandolapril.Approved, Investigational
MuzolimineTrandolapril may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Trandolapril.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Trandolapril.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Trandolapril.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Trandolapril.Approved
NadololTrandolapril may increase the hypotensive activities of Nadolol.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Trandolapril.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Trandolapril.Approved
NaftopidilTrandolapril may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Trandolapril.Approved, Vet Approved
NebivololTrandolapril may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Trandolapril.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Trandolapril.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Trandolapril.Withdrawn
NicardipineTrandolapril may increase the hypotensive activities of Nicardipine.Approved, Investigational
NicorandilNicorandil may increase the vasodilatory activities of Trandolapril.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nifedipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Trandolapril.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Trandolapril.Approved
NiguldipineTrandolapril may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineTrandolapril may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Trandolapril.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Trandolapril.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Trandolapril.Approved
NitrendipineTrandolapril may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Trandolapril.Approved
NitroaspirinThe therapeutic efficacy of Trandolapril can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nitroglycerin.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Trandolapril.Approved, Investigational
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Trandolapril.Approved
ObinutuzumabTrandolapril may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Trandolapril.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Trandolapril.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Trandolapril.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Trandolapril.Approved
OmapatrilatTrandolapril may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Trandolapril.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Trandolapril.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Trandolapril.Approved
OxprenololTrandolapril may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Trandolapril.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Trandolapril.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Papaverine.Approved, Investigational
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Trandolapril.Approved
PargylinePargyline may increase the hypotensive activities of Trandolapril.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Trandolapril.Approved, Investigational
PenbutololTrandolapril may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Trandolapril.Approved, Investigational, Vet Approved
PentoliniumTrandolapril may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Trandolapril.Approved, Investigational
PerindoprilTrandolapril may increase the hypotensive activities of Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Trandolapril.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Trandolapril.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Trandolapril.Approved, Investigational
PhenoxybenzamineTrandolapril may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Trandolapril.Withdrawn
PhentolamineTrandolapril may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Trandolapril.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Trandolapril.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Trandolapril.Approved
PindololTrandolapril may increase the hypotensive activities of Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Trandolapril.Approved, Investigational
PiretanidePiretanide may increase the hypotensive activities of Trandolapril.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Trandolapril.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Trandolapril.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Trandolapril.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Trandolapril.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Trandolapril.Withdrawn
Platelet Activating FactorTrandolapril may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideThe risk or severity of hypotension can be increased when Polythiazide is combined with Trandolapril.Approved
PotassiumPotassium may increase the hyperkalemic activities of Trandolapril.Approved, Investigational
Potassium bicarbonatePotassium bicarbonate may increase the hyperkalemic activities of Trandolapril.Approved
Potassium ChloridePotassium Chloride may increase the hyperkalemic activities of Trandolapril.Approved, Withdrawn
Potassium CitratePotassium Citrate may increase the hyperkalemic activities of Trandolapril.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Trandolapril.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Trandolapril.Experimental, Investigational
PrazosinPrazosin may increase the hypotensive activities of Trandolapril.Approved
PregabalinThe risk or severity of angioedema can be increased when Trandolapril is combined with Pregabalin.Approved, Illicit, Investigational
PrimidonePrimidone may increase the hypotensive activities of Trandolapril.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Trandolapril.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Trandolapril.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Trandolapril.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Trandolapril.Approved, Investigational, Vet Approved
PropranololTrandolapril may increase the hypotensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Trandolapril.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Trandolapril.Experimental
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Trandolapril.Approved
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Trandolapril.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Trandolapril is combined with Quetiapine.Approved
QuinaprilTrandolapril may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinethazoneThe risk or severity of hypotension can be increased when Quinethazone is combined with Trandolapril.Approved
QuinineQuinine may increase the hypotensive activities of Trandolapril.Approved
RamiprilRamipril may increase the hypotensive activities of Trandolapril.Approved
RasagilineRasagiline may increase the hypotensive activities of Trandolapril.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Trandolapril.Approved
RemikirenRemikiren may increase the hypotensive activities of Trandolapril.Approved
RescinnamineTrandolapril may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Trandolapril.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Trandolapril.Approved, Experimental, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Trandolapril.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Trandolapril.Approved
RisperidoneTrandolapril may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabTrandolapril may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Trandolapril.Approved, Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Trandolapril.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Trandolapril.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Trandolapril.Approved
SacubitrilThe risk or severity of angioedema can be increased when Trandolapril is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Trandolapril.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Trandolapril.Approved
Salicylic acidThe therapeutic efficacy of Trandolapril can be decreased when used in combination with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Trandolapril.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Trandolapril.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Trandolapril.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Trandolapril.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Trandolapril.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Trandolapril.Approved, Investigational, Vet Approved
SelexipagTrandolapril may increase the hypotensive activities of Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Trandolapril.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Trandolapril.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Trandolapril.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Trandolapril.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Trandolapril.Approved, Investigational
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Trandolapril.Approved
SirolimusThe risk or severity of angioedema can be increased when Sirolimus is combined with Trandolapril.Approved, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Trandolapril.Approved, Investigational
SitaxentanTrandolapril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of hypotension, nitritoid reactions, facial flushing, nausea, and vomiting can be increased when Trandolapril is combined with Sodium aurothiomalate.Approved, Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Trandolapril.Approved, Investigational
Sodium phosphateTrandolapril may increase the nephrotoxic activities of Sodium phosphate.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Trandolapril.Approved
SpiraprilTrandolapril may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Trandolapril.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Trandolapril.Investigational
St. John's WortThe metabolism of Trandolapril can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Trandolapril.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Trandolapril.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Trandolapril.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Trandolapril.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Trandolapril.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Trandolapril.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Trandolapril.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Trandolapril.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Trandolapril.Approved, Investigational
TalinololTrandolapril may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Trandolapril.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Trandolapril.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Trandolapril.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Trandolapril.Approved, Investigational
TemocaprilTrandolapril may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Trandolapril is combined with Temsirolimus.Approved
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Trandolapril.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Trandolapril.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Trandolapril.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Trandolapril is combined with Terazosin.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Trandolapril.Approved
TerlipressinTrandolapril may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineTrandolapril may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Trandolapril.Approved, Investigational, Withdrawn
TheodrenalineTrandolapril may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Trandolapril.Approved
ThiamylalThiamylal may increase the hypotensive activities of Trandolapril.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Trandolapril.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Trandolapril.Approved, Withdrawn
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Trandolapril.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Trandolapril.Approved
TiboloneTrandolapril may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenTrandolapril may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Trandolapril.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Trandolapril.Investigational
TipranavirThe serum concentration of Trandolapril can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of hypotension can be increased when Tizanidine is combined with Trandolapril.Approved, Investigational
TolazolineTrandolapril may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Trandolapril.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Trandolapril.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Trandolapril.Approved
TolonidineTrandolapril may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Trandolapril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Trandolapril.Approved
TorasemideTorasemide may increase the hypotensive activities of Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Trandolapril.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Trandolapril.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Trandolapril.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Trandolapril.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Trandolapril.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Trandolapril.Approved, Investigational, Nutraceutical
TriamtereneTriamterene may increase the hyperkalemic activities of Trandolapril.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Trandolapril.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Trandolapril.Experimental
TrichlormethiazideThe risk or severity of hypotension can be increased when Trichlormethiazide is combined with Trandolapril.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Trandolapril.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Trandolapril.Approved, Investigational
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Trandolapril.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Trandolapril.Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Trandolapril.Investigational
Trolamine salicylateThe therapeutic efficacy of Trandolapril can be decreased when used in combination with Trolamine salicylate.Approved
UdenafilUdenafil may increase the antihypertensive activities of Trandolapril.Approved, Investigational
UnoprostoneTrandolapril may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Trandolapril.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Trandolapril.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Trandolapril.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Trandolapril.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Trandolapril.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Trandolapril.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Trandolapril.Approved, Investigational
VincamineTrandolapril may increase the hypotensive activities of Vincamine.Experimental
VinpocetineTrandolapril may increase the hypotensive activities of Vinpocetine.Investigational
XipamideTrandolapril may increase the hypotensive activities of Xipamide.Experimental
XylometazolineTrandolapril may increase the hypotensive activities of Xylometazoline.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Trandolapril.Approved, Investigational, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Trandolapril.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Trandolapril.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Trandolapril.Approved, Investigational, Withdrawn
ZofenoprilTrandolapril may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Trandolapril.Withdrawn
Food Interactions
  • Herbs that may attenuate the antihypertensive effect of trandolapril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of trandolapril.
  • Take without regard to meals.
  • Trandolapril may decrease the excretion of potassium. Salt substitutes containing potassium may increase the risk of hyperkalemia.

References

Synthesis Reference

Narendra Joshi, Shekhar Bhirud, Buddhavarapu Ramam, Arjun Bodkhe, "Process for the preparation of intermediates of trandolapril and use thereof for the preparation of trandolapril." U.S. Patent US20060079698, issued April 13, 2006.

US20060079698
General References
  1. Berl T: Review: renal protection by inhibition of the renin-angiotensin-aldosterone system. J Renin Angiotensin Aldosterone Syst. 2009 Mar;10(1):1-8. doi: 10.1177/1470320309102747. [PubMed:19286752]
  2. Conen H, Brunner HR: Pharmacologic profile of trandolapril, a new angiotensin-converting enzyme inhibitor. Am Heart J. 1993 May;125(5 Pt 2):1525-31. [PubMed:8480624]
  3. Diaz A, Ducharme A: Update on the use of trandolapril in the management of cardiovascular disorders. Vasc Health Risk Manag. 2008;4(6):1147-58. [PubMed:19337528]
  4. Guay DR: Trandolapril: a newer angiotensin-converting enzyme inhibitor. Clin Ther. 2003 Mar;25(3):713-75. [PubMed:12852701]
  5. Jouquey S, Stepniewski JP, Hamon G: Trandolapril dose-response in spontaneously hypertensive rats: effects on ACE activity, blood pressure, and cardiac hypertrophy. J Cardiovasc Pharmacol. 1994;23 Suppl 4:S16-8. [PubMed:7527096]
  6. Reynolds NA, Wagstaff AJ, Keam SJ: Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension. Drugs. 2005;65(13):1893-914. [PubMed:16114984]
  7. Rubio-Guerra AF, Vargas-Robles H, Vargas-Ayala G, Rodriguez-Lopez L, Escalante-Acosta BA: The effect of trandolapril and its fixed-dose combination with verapamil on circulating adhesion molecules levels in hypertensive patients with type 2 diabetes. Clin Exp Hypertens. 2008 Oct;30(7):682-8. doi: 10.1080/10641960802251941. [PubMed:18855271]
  8. Sanbe A, Tanonaka K, Kobayasi R, Takeo S: Effects of long-term therapy with ACE inhibitors, captopril, enalapril and trandolapril, on myocardial energy metabolism in rats with heart failure following myocardial infarction. J Mol Cell Cardiol. 1995 Oct;27(10):2209-22. [PubMed:8576937]
  9. Torp-Pedersen C, Kober L: Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet. 1999 Jul 3;354(9172):9-12. [PubMed:10406358]
  10. Authors unspecified: Trandolapril: an ACE inhibitor for treatment of hypertension. Med Lett Drugs Ther. 1996 Nov 22;38(988):104-5. [PubMed:8941256]
  11. Wiseman LR, McTavish D: Trandolapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension. Drugs. 1994 Jul;48(1):71-90. [PubMed:7525196]
  12. Zannad F: Trandolapril. How does it differ from other angiotensin converting enzyme inhibitors? Drugs. 1993;46 Suppl 2:172-81; discussion 182. [PubMed:7512472]
External Links
Human Metabolome Database
HMDB0014660
KEGG Drug
D00383
PubChem Compound
5484727
PubChem Substance
46508300
ChemSpider
4588590
BindingDB
50369775
ChEBI
9649
ChEMBL
CHEMBL1519
Therapeutic Targets Database
DAP000583
PharmGKB
PA451737
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Trandolapril
ATC Codes
C09AA10 — TrandolaprilC09BB10 — Trandolapril and verapamil
AHFS Codes
  • 24:32.04 — Angiotensin-converting Enzyme Inhibitors
MSDS
Download (57.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers2
1CompletedTreatmentHealthy Volunteers2
3CompletedTreatmentBMI >30 kg/m2 / High Blood Pressure (Hypertension)1
4CompletedTreatmentCoronary Artery Disease / High Blood Pressure (Hypertension)1
4CompletedTreatmentDiabetes Mellitus (DM) / High Blood Pressure (Hypertension)1
4CompletedTreatmentDiabetes Mellitus (DM) / High Blood Pressure (Hypertension) / Proteinuria1
4CompletedTreatmentHeart Failure, Unspecified / Ventricular Dysfunction, Left1
4CompletedTreatmentHigh Blood Pressure (Hypertension)3
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Metabolic Syndromes1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Induction of intra-operative hypotension1
4Unknown StatusTreatmentAortic Valve Stenosis1

Pharmacoeconomics

Manufacturers
  • Abbott laboratories pharmaceutical products div
  • Aurobindo pharma ltd
  • Cipla ltd
  • Corepharma llc
  • Dr reddys laboratories ltd
  • Epic pharma llc
  • Invagen pharmaceuticals inc
  • Lupin ltd
  • Mylan pharmaceuticals inc
  • Teva pharmaceuticals usa
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
CapsuleOral0.5 mg
CapsuleOral1 mg
CapsuleOral2 mg
CapsuleOral4 mg
TabletOral4 mg/1
Tablet, extended releaseOral
Tablet, film coated, extended releaseOral
TabletOral1 mg/1
TabletOral2 mg/1
Prices
Unit descriptionCostUnit
Tarka 1-240 mg Controlled Release Tabs3.46USD tab
Tarka 4-240 mg Controlled Release Tabs3.4USD tab
Tarka 1-240 mg tablet sa3.33USD tablet
Tarka 2-180 mg tablet sa3.33USD tablet
Tarka 2-240 mg Controlled Release Tabs3.33USD tab
Tarka 2-240 mg tablet sa3.33USD tablet
Tarka 4-240 mg tablet sa3.33USD tablet
Tarka 2-180 mg Controlled Release Tabs3.29USD tab
Mavik 2 mg tablet1.61USD tablet
Mavik 4 mg tablet1.61USD tablet
Mavik 1 mg tablet1.47USD tablet
Trandolapril 1 mg tablet1.24USD tablet
Trandolapril 2 mg tablet1.23USD tablet
Trandolapril 4 mg tablet1.23USD tablet
Mavik 4 mg Capsule1.03USD capsule
Mavik 2 mg Capsule0.83USD capsule
Mavik 1 mg Capsule0.72USD capsule
Mavik 0.5 mg Capsule0.42USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5744496No1995-04-282015-04-28Us
CA2023089No2003-01-142010-08-10Canada
CA1341206No2001-03-202018-03-20Canada

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)119-123 °CNot Available
logP3.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0207 mg/mLALOGPS
logP1.31ALOGPS
logP1.95ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)3.8ChemAxon
pKa (Strongest Basic)5.21ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area95.94 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity115.79 m3·mol-1ChemAxon
Polarizability46.79 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9303
Blood Brain Barrier-0.8908
Caco-2 permeable-0.8501
P-glycoprotein substrateSubstrate0.7744
P-glycoprotein inhibitor IInhibitor0.5527
P-glycoprotein inhibitor IIInhibitor0.7759
Renal organic cation transporterNon-inhibitor0.8336
CYP450 2C9 substrateNon-substrate0.8227
CYP450 2D6 substrateNon-substrate0.8935
CYP450 3A4 substrateSubstrate0.5515
CYP450 1A2 substrateNon-inhibitor0.915
CYP450 2C9 inhibitorNon-inhibitor0.785
CYP450 2D6 inhibitorNon-inhibitor0.9018
CYP450 2C19 inhibitorNon-inhibitor0.796
CYP450 3A4 inhibitorNon-inhibitor0.5339
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6906
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9188
BiodegradationNot ready biodegradable0.9587
Rat acute toxicity2.2048 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9811
hERG inhibition (predictor II)Non-inhibitor0.5531
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Dipeptides
Alternative Parents
Alpha amino acid esters / N-acyl-L-alpha-amino acids / Alpha amino acid amides / Indoles and derivatives / Pyrrolidine carboxylic acids / N-acylpyrrolidines / Aralkylamines / Fatty acid esters / Benzene and substituted derivatives / Dicarboxylic acids and derivatives
show 10 more
Substituents
Alpha-dipeptide / Alpha-amino acid ester / N-acyl-l-alpha-amino acid / N-acyl-alpha-amino acid / N-acyl-alpha amino acid or derivatives / Alpha-amino acid amide / Alpha-amino acid or derivatives / Indole or derivatives / N-acylpyrrolidine / Pyrrolidine carboxylic acid
show 28 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent...
Gene Name
ACE
Uniprot ID
P12821
Uniprot Name
Angiotensin-converting enzyme
Molecular Weight
149713.675 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Piepho RW: Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm. 2000 Oct 1;57 Suppl 1:S3-7. [PubMed:11030016]
  3. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Triglyceride lipase activity
Specific Function
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acy...
Gene Name
CES1
Uniprot ID
P23141
Uniprot Name
Liver carboxylesterase 1
Molecular Weight
62520.62 Da
References
  1. Zhu HJ, Appel DI, Johnson JA, Chavin KD, Markowitz JS: Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril. Biochem Pharmacol. 2009 Apr 1;77(7):1266-72. doi: 10.1016/j.bcp.2008.12.017. Epub 2009 Jan 6. [PubMed:19185566]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name
SLC15A1
Uniprot ID
P46059
Uniprot Name
Solute carrier family 15 member 1
Molecular Weight
78805.265 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Peptide:proton symporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name
SLC15A2
Uniprot ID
Q16348
Uniprot Name
Solute carrier family 15 member 2
Molecular Weight
81782.77 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951]

Drug created on June 13, 2005 07:24 / Updated on February 21, 2018 17:12